NAC's portfolio includes 60 viral and infectious disease products, including pathogen receptors, virus-like particles and antibodies for immunoassay technologies, and vaccine development and quality control solutions. The global supplier also offers antigens for SARS-CoV-2 to help researchers respond to the COVID-19 pandemic.

The acquisition will bolster LGC's product offerings in the in vitro diagnostics (IVD) market, according to the company. LGC's existing IVD offerings include quality assurance tools, immunoassay reagents, disease-state plasma, and probes and primers for molecular diagnostics.

Companion diagnostics survive COVID-19 with small nick
The COVID-19 crisis has had a slightly negative, but not critical, impact on the market for companion diagnostics, according to a new market report from...

An update on RNA extraction kit supply due to COVID-19
The extraordinary demand for COVID-19 polymerase chain reaction testing has strained the production capabilities of vendors in the nucleic acid preparation...